Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome

被引:40
作者
Tektonidou, MG
Ioannidis, JPA
Moyssakis, I
Boki, KA
Vassiliou, V
Vlachoyiannopoulos, PG
Kyriakidis, MK
Moutsopoulos, HM
机构
[1] Univ Athens, Sch Med, Dept Pathophysiol, GR-11527 Athens, Greece
[2] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin & Mol Epidemiol Unit, GR-45110 Ioannina, Greece
[3] Laikon Gen Hosp, Dept Cardiol, Athens, Greece
关键词
D O I
10.1136/ard.60.1.43
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-To evaluate the prevalence of diastolic dysfunction in patients with anticardiolipin antibodies (aCL) and to examine whether the antiphospholipid syndrome (APS) is associated with diastolic dysfunction independently of valvular abnormalities and systolic dysfunction. Methods-Pulsed, continuous, colour Doppler echocardiography was performed in 179 subjects, of whom 15 were excluded from the analysis because of systolic dysfunction or severe valvular disease. The remaining 164 subjects included 29 patients with primary APS, 26 patients with secondary APS (APS in the presence of systemic lupus erythematosus (SLE)), and 30 patients with SLE and aCL but without BPS; 43 patients with SLE without aCL and 36 normal volunteers served as control groups. Results-The groups compared differed significantly in all measures of right ventricular function. There was a gradation of increasing diastolic function impairment as manifested by prolonged deceleration time (DT) and isovolumic relaxation time (IVRT) across the groups of patients with SLE without aCL, SLE with aCL, secondary APS, and primary APS. Differences in left ventricular diastolic function measures were less prominent. in regression analysis, DT increased by 19.6 ms (p=0.002) in the presence of primary APS and by 20.1 ms (p=0.038) in the presence of pulmonary hypertension. The titre of IgG aCL was the strongest predictor of a prolonged IVRT. Conclusion-Diastolic dysfunction, in particular of the right ventricle-that is, independent of valvular disease and systolic dysfunction, is a prominent feature of APS and may be related to the pathogenesis of the syndrome.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 44 条
[1]   PRELIMINARY CLASSIFICATION CRITERIA FOR THE ANTIPHOSPHOLIPID SYNDROME WITHIN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ALARCONSEGOVIA, D ;
PEREZVAZQUEZ, ME ;
VILLA, AR ;
DRENKARD, C ;
CABIEDES, J .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1992, 21 (05) :275-286
[2]  
ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P482
[3]  
ASHERSON RA, 1986, J RHEUMATOL, V13, P1
[4]   IMMUNOPATHOLOGY OF CARDIAC LESIONS IN FATAL SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
BIDANI, AK ;
ROBERTS, JL ;
SCHWARTZ, MM ;
LEWIS, EJ .
AMERICAN JOURNAL OF MEDICINE, 1980, 69 (06) :849-858
[5]   CARDIAC INVOLVEMENT IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME [J].
BRENNER, B ;
BLUMENFELD, Z ;
MARKIEWICZ, W ;
REISNER, SA .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (04) :931-936
[6]   FATAL CARDIAC-FAILURE DUE TO MYOCARDIAL MICROTHROMBI IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
BROWN, JH ;
DOHERTY, CC ;
ALLEN, DC ;
MORTON, P .
BRITISH MEDICAL JOURNAL, 1988, 296 (6635) :1505-1505
[7]  
BRUCATO A, 1994, J RHEUMATOL, V21, P942
[8]   AORTIC-INSUFFICIENCY AND MITRAL REGURGITATION IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS AND THE ANTIPHOSPHOLIPID SYNDROME [J].
CHARTASH, EK ;
LANS, DM ;
PAGET, SA ;
QAMAR, T ;
LOCKSHIN, MD .
AMERICAN JOURNAL OF MEDICINE, 1989, 86 (04) :407-412
[9]  
COUDRAY N, 1995, BRIT HEART J, V74, P531
[10]   ECHOCARDIOGRAPHIC ASSESSMENT OF LEFT-VENTRICULAR HYPERTROPHY - COMPARISON TO NECROPSY FINDINGS [J].
DEVEREUX, RB ;
ALONSO, DR ;
LUTAS, EM ;
GOTTLIEB, GJ ;
CAMPO, E ;
SACHS, I ;
REICHEK, N .
AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (06) :450-458